New research demonstrates how specially engineered bacteria taken orally can operate as a delivery system for vaccines and antiviral therapies.

This was the stock's second consecutive day of losses.

Viral infectious diseases pose significant challenges due to the rapid evolution of viruses through mutations. This was particularly evident during the COVID-19 pandemic, when emerging variants of ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

The COVID-19 pandemic increased public awareness of the importance of mask use for personal protection. However, when the ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

DXC Technology sees first-quarter adjusted EPS of between 55 cents and 65 cents per share, versus the 77 cent analyst estimate, and revenue in a range of $3.04 billion to $3.09 billion, versus the ...

The global In Vitro Diagnostics Market is projected to be valued at USD 108.3 billion in 2024 and reach USD 150.13 billion by ...

The global managed services market size is projected to reach USD 731.08 billion by 2030, according to a new study conducted by Grand View Research, Inc. The market is anticipated to grow at a CAGR of ...

FY25 earnings insights from DXC Technology. Key takeaways: improved bookings, leadership stability, and operational rebuilding.